A phase 2 study for patients with HR-positive, HER2-negative metastatic breast cancer will be evaluating alisertib plus ...

Elacestrant, a selective estrogen receptor degrader, demonstrated significant improvements in progression-free survival (PFS) ...

Sarah Sammons, MD, discusses some of the challenges seen with different regimens for HER2-positive metastatic breast cancer ...

An expert discusses the next steps for patients with metastatic breast cancer after their disease no longer responds to ...

A new study found that Black women are more likely to die from breast cancer than white women, regardless of the tumor ...

Novartis has secured European Commission approval for Kisqali® (ribociclib) in combination with endocrine therapy (ET) as an ...

Basel: Novartis has announced that the European Commission (EC) has approved Kisqali (ribociclib) in combination with an ...

Novartis Kisqali receives European approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence: Basel Thursday, November 28, 2024, 09: ...

Both rare and aggressive, triple-negative breast cancer accounts for 10-15% of all breast cancers. Dr. Bhardwaj says, “TNBC ...

Findings from the HELEN-006 trial suggest a potential shift in neoadjuvant treatment practices for patients with HER2-positive early breast cancer, specifically using nab-paclitaxel to reduce ...

AZ and Daiichi Sankyo already claimed FDA approval for the HER2-low indication ... with both HR-positive and HR-negative disease who previously have had limited treatment options in the late ...